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1. Introduction
Peganum harmala  L. (Zygophyllaceae), the so-
called harmal, grows spontaneously in
uncultivated and steppes areas in semiarid and
pre-deserted regions in south Spain and South-
East Morocco [1]. Harmala alkaloids are
distributed widely in some medicinal plants
and are found endogenously in mammalian
tissues. Harmala alkaloids have a wide
spectrum of pharmacological actions in the
central nervous system such as tremorogenesis
[2], hypothermia [3,4], hallucinogenesis [5,6],
central monoamine oxidase inhibition [7-9],
convulsive or anticonvulsive actions and
binding to various receptors including 5-HT
receptors and the benzodiazepine binding site
of GABAA receptors [10]. In addition, these
compounds also have antioxidative [11],
platelet aggregation inhibitory and
immunomodulatory effects [12-13]. There are
also some reports concerning the
cardiovascular actions of harmala alkaloids,
such as systemic arterial blood pressure and
total peripheral vascular resistance reduction
by harmine, or an in vivo vasorelaxant effect
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of Harman [14]. In addition, we reported in a
recent work the vascular relaxant effect of a
methanolic extract from seeds of P. harmala
L. (MEP) [15].
In the present study we isolated and
characterize spectroscopycally two alkaloids
from such extract and evaluated their cytotoxic
activity in three human cancer cell lines.
2. Material and methods
2.1 Plant
Peganum harmala  L. (Zygophyllaceae) fresh
seeds were collected from the medium of atlas
region (Morocco), in May 2002 and botanically
identified by botanical section of (U.F.R:
Naturals Products), Faculty of Medicine and
Pharmacy. Rabat; where a voucher specimen
is preserved.
2.2 Extraction of methanolic extract (ME) and
natural compound
Fresh and powdered seeds were successively
extracted in a soxhlet apparatus with Petrol-ether
(60-80°C), CHCl3 , EtOAc and MeOH. The
obtained extract was concentrated under
reduced pressure to yield dry residues: 0.67,
1.42, 2.8, 31% (w/w), respectively. The naturals
compound (Harmaline and Harmine) were
extracted from the last fraction (Methanolic
extract); this fraction was chromatographed on
silica gel column, and the elution was started
with CHCl3 following with CHCl3 containing
increasing amount of MeOH.
All fractions obtained from this silica gel
column were subjected to TLC (thin layer
chromatography) examination using CHCl3-
MeOH (9:1). Fractions with similar migration
times were combined. Harmine and
harmaline were isolated by crystallisation
from their fractions using in CHCl3 and MeOH
respectively. the compounds were analysed
by TLC, 1H-NMR, 13C-NMR (Nuclear Magnetic
Resonance) and mass spectra.
2.3 Human tumour cell line
The following three human cancer cell lines
were used in these experiments: the human
renal adenocarcinoma (TK-10), the human
breast adenocarcinoma (MCF-7) and the
human melanoma (UACC-62) cell lines. They
were kindly provided by Dr. G. Cragg,
Department of NCI, Maryland, USA.
The human tumour cytotoxicities were
determined following protocols established by
the National Cancer Institute, National Institute
of Health [16]. TK-10, MCF-7 and UACC-62
cell lines were cultured in RPMI 1640 medium
(Biowhittaker) containing 20% fetal calf serum,
20mM L-glutamine, 100U/ml penicillin and
100 µg/ml streptomycin. All cell lines were
maintained at 37°C in a 5% CO2 atmosphere
with 95% humidity.
2.4 Cytotoxicity assay
For the assay, cells were detached with 0.1%
trypsin-EDTA (Sigma) to make single-cell
suspensions, and viable cells were counted
using a Coulter counter and diluted with
medium to give final concentrations of 15x104
5x104 and 100x104 cells/ml for TK-10, MCF-7
and UACC-62 respectively. 100µl/well of these
cell suspensions were seeded in 96-well
microtiter plates and incubated to allow for
cell attachment.
After 24 h the cells were treated with the serial
concentrations of compounds or extracts. They
were initially dissolved in an amount of 100%
DMSO (10 mM) and further diluted in medium
to produce 5 concentrations. 100µL/well of
each concentration was added to the plates to
obtain final concentrations of 10-4, 10-5, 10-6,
10-7 and 10-8 M for the compounds and 250,
25, 2.5, 0.25 and 0.025µg/mL for the extract.
The DMSO concentration for the tested
dilutions was not greater than 0.25% (V/V), the
same as in solvent control wells. The final
volume in each well was 200µl. The plates were
incubated for 48 h.
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Sulphorhodamine B method: This colorimetric
assay estimates cell number indirectly by
staining total cellular protein with the dye SRB.
After incubating 48 h, adherent cell cultures
were fixed in situ by adding 50µl of cold 50%
(W/V) trichloroacetic acid (TCA) and
incubating for 60 min. at 4ºC. The supernatant
is then discarded, and the plates are washed
five times with deionised water and dried.
One hundred ml of SRB solution (0.4% wt/vol
in 1% acetic acid) is added to each microtiter
well and the culture was incubated for 30 min
at room temperature. Unbound SRB was
removed by washing five times with 1% acetic
acid. Then the plates were air-dried. Bound
stain is solubilized with Tris buffer, and the
optical densities were read on an automated
spectrophotometric plate reader at a single
wavelength of 492 nm.
At the end, IC50 values were calculated and at
least three independent experiments were
carried out for each compound or extract. Data
are given as the mean ± SEM.
3. Results and discussion
3.1. Chemistry
Harmine and harmaline were isolated by
crystallisation after silica gel column
separation. The TLC analysis revealed two
spots (blue and violet) under UV light with Rf
values 0.62 (harmine) and 0.36 (harmaline).
This data are in agreement with those reported
in the literature (0.64 and 0.35
respectively)[17]. Furthermore, the 1H-NMR
and 13C-NMR data illustrated in Table 1
revealed that these compounds were harmine
and harmaline (Fig 1).
B.
C    Harmaline          Harmine
             (50 MHz, CDCl3) (50 MHz, DMSO)
1 161.889 14.934
2 - -
3 41.839 137.762
4 19.908 111.947
5 122.212 122.625
6 115.754 109.068
7 164.575 160.074
8 94.049 94.57
9 - -
10 125.029 134.534
11 119.038 114.833
12 125.549 127.206
13 144.201 141.274
CH3-1 19.05 20.344
CH3O-7 55.704 55.319
(d = doublet, dd = doublet doublet, m = multiplet,
 s = singulet)
Table I.
1H (A)- and 13C (B)-NMR data of harmaline and harmine in CDCl3 and DMSO, respectively.
A.       Harmaline (200 MHz, CDCl3)       Harmine (200 MHz, DMSO)
H δ [ppm] multiplicity J [Hz] H δ [ppm] multiplicity J [Hz]
N H 11.54 s N H 11.42 s
H-8 7.04 d 1,9 H-8 7.00 d 2.1
H-6 6.80 dd 1,9 /8,9 H-6 6.83 dd 2.1/8.6
H-5 7.42 d 8,9 H-5 8.04 d 8.6
H-4 3.14 m H-4 7.79 d 5.3
H-3 3.88 m H-3 8.14 d 5.3
OCH3 3.83 s OCH 3 3.86 s
CH3 2.99 s CH3 2.71 s
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3.2. Cytotoxicity assay
Although the role of nitric oxide in tumor
biology remains incompletely understood, it
is known to have both tumour promoting and
inhibitory effects, presumed to be dependent
on its local concentration within the tumor. The
p53 tumor suppressor gene may influence its
production, and NO appears to be pivotal in
the angiogenic processs being necessary for
solid malignant tumor development.
In addition, nitric oxide has been shown to
induce cytostasis and cell cycle arrest on the
human breast cancer cell line MDA-MB-231
[18,19]. Bearing in mind that the alkaloids
harmine and harmaline have been shown to
induce NO production from cultured rat aortic
endothelial cells [14], we considered the
possible anticancer effect of such alkaloids.
Therefore, we assayed the cytotoxic activity,
on the human cancer cell lines TK-10, MCF-7
and UACC-62, of these alkaloids as well as
the plant extract where they were isolated,
being the results depicted in Table 2.
The antineoplastic agent etoposide was taken
as positive control for comparison with the
tested compounds. The extract and the
alkaloids were active on the three cancer cell
lines at the recommended USA National
Cancer Institute (NCI), although they were less
active than etoposide. Harmaline’s activity was
slightly higher than the observed for harmaline,
suggesting that the change of β-carboline to
dihydro-β-carboline might be increasing the
anticancer activity.
The alkaloids concentrations producing an
inhibition of the growth by 50% (IC50) on the
three human cancer cell lines were similar to
the concentrations required for the induction
of NO production by such compounds [14].
Therefore, we might think that their anticancer
action is mediated by NO production.
Table 2
Cytotoxic activity (expressed as IC50 ± SEM values) of harmine, harmaline,
methanolic extract where they were isolated, and the positive control (etoposide)
on the human cancer cell lines TK-10, MCF-7 and UACC-62.
n TK-10 MCF-7 UACC-62
ME 3 IC50 (µg/mL) 38.3 ± 2.3 25.3 ± 4.2 26.6 ± 3.1
Harmine 3 IC50 (µM) 40.5 ± 6.8 29.3 ±3.5 18.0 ± 0.7
Harmaline 3 IC50 (µM) 27.5 ± 3.2 16.4 ± 2.5 11.1 ± 1.5
Etoposide 3 IC50 (µM) 9.95 ± 0.08 0.87 ± 0.21 1.13 ± 0.21
n: number of independent experiments.
(B)
Fig 1. Chemical structure of harmine (A)
and harmaline (B).
(A)
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However, despite the fact that harmine showed
less NO production activity that harmaline, its
anticancer activity in our cancer cell lines was
higher, suggesting the involvement of other
mechanisms in its anticancer action.
In this way, Ayoub et al., [20] have reported
that harmalol (an indole alkaloid from P.
harmala ) inhibited the proliferation of K562-
Leukaemic tumor cell line by inhibiting DNA
synthesis and cell division. A previous work
has shown that β-carbolines could intercalate
into DNA, this effect may cause inhibition of
DNA topoisomerases leading to a cytotoxic
effect. Accordingly, Sobhani et al., [21] have
reported that P. harmala seeds extract inhibit
human DNA topoisomerase I.
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